400-920-2911 sales@csnpharm.cn
您的位置 : 首页 / Cell Cycle / PLK / 伏拉塞替
CAS No.: 755038-65-4
Synonyms: BI 6727;伏拉塞替
BI6727 is an ATP-competitive kinase inhibitor from the dihydropteridinone class of compounds.
生物活性
靶点 | PLK1 IC50:0.87nM |
动物研究 | |||||||||||||||||||||||||||||||||||||
剂量 | Mice: 30 mg/kg[2] (i.v.), 40 mg/kg[1] (i.v.), 50 mg/kg[1] (p.o.) Rat: 10 mg/kg[1] (i.v.), 30 mg/kg[1] (p.o.) | ||||||||||||||||||||||||||||||||||||
给药途径 | i.v., p.o. | ||||||||||||||||||||||||||||||||||||
动物药代数据 |
|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|---|---|---|---|---|
NCT01023958 | Neoplasms | Phase 2 | Completed | - | United States, California ... more >> 1230.2.5 Boehringer Ingelheim Investigational Site Beverly Hills, California, United States 1230.2.10 Boehringer Ingelheim Investigational Site Los Angeles, California, United States United States, Florida 1230.2.34 Boehringer Ingelheim Investigational Site Miami, Florida, United States 1230.2.29 Boehringer Ingelheim Investigational Site Orlando, Florida, United States United States, Illinois 1230.2.6 Boehringer Ingelheim Investigational Site Chicago, Illinois, United States 1230.2.17 Boehringer Ingelheim Investigational Site Joliet, Illinois, United States United States, Louisiana 1230.2.24 Boehringer Ingelheim Investigational Site Metairie, Louisiana, United States United States, Maryland 1230.2.1 Boehringer Ingelheim Investigational Site Baltimore, Maryland, United States United States, Nevada 1230.2.25 Boehringer Ingelheim Investigational Site Las Vegas, Nevada, United States 1230.2.36 Boehringer Ingelheim Investigational Site Las Vegas, Nevada, United States United States, New Hampshire 1230.2.19 Boehringer Ingelheim Investigational Site Lebanon, New Hampshire, United States United States, New York 1230.2.20 Boehringer Ingelheim Investigational Site New York, New York, United States 1230.2.23 Boehringer Ingelheim Investigational Site New York, New York, United States United States, North Carolina 1230.2.12 Boehringer Ingelheim Investigational Site Charlotte, North Carolina, United States United States, Pennsylvania 1230.2.4 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States United States, Texas 1230.2.38 Boehringer Ingelheim Investigational Site Beaumont, Texas, United States 1230.2.41 Boehringer Ingelheim Investigational Site Tyler, Texas, United States 1230.2.43 Boehringer Ingelheim Investigational Site Webster, Texas, United States United States, Virginia 1230.2.44 Boehringer Ingelheim Investigational Site Fairfax, Virginia, United States Taiwan 1230.2.51 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1230.2.50 Boehringer Ingelheim Investigational Site Taipei, Taiwan Collapse << |
NCT00969553 | Neoplasms | Phase 1 | Completed | - | Taiwan ... more >> 1230.16.886002 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1230.16.886001 Boehringer Ingelheim Investigational Site Taipei, Taiwan Collapse << |
NCT01023958 | - | - | Completed | - | - |
实验方案
技术信息
CAS号 | 755038-65-4 | 储存条件 |
|
|||||||||||
分子式 | C34H50N8O3 | 运输 | 蓝冰 | |||||||||||
分子量 | 618.81 | 别名 | BI 6727;伏拉塞替 | |||||||||||
溶解度 |
|
动物实验配方 |
|
Cell Lines | Concentration | Assay Type | Time | Activity Description | Data Sources |
---|
5637 | - | Growth Inhibition Assay | 48 h | IC50=1165.14 nM | 23792639 |
A431 | 0-30 nM | Growth Inhibition Assay | 1-4 d | inhibits cell growth in both dose- and time-dependent manner | 23891096 |
BRO | - | Growth Inhibition Assay | - | EC50 = 11 nM | 19383823 |
DU145 | 10/50/250 nM | Growth Inhibition Assay | 24 h | IC50<10 nM | 23884428 |
FaDu | 0-1000 nM | Growth Inhibition Assay | 1-4 d | inhibits cell growth in both dose- and time-dependent manner | 23891096 |
GRANTA-519 | - | Growth Inhibition Assay | - | EC50 = 15 nM | 19383823 |
HCC1428/LTED | 2.5-40 nM | Growth Inhibition Assay | 5 d | inhibits cell growth in a dose-dependent manner | 25480943 |
HCT 116 | - | Growth Inhibition Assay | - | EC50 = 23 nM | 19383823 |
HL-60 | - | Growth Inhibition Assay | - | EC50 = 32 nM | 19383823 |
HUCCT-1 | 200 nM | Apoptosis Assay | 24 h | induces apoptosis | 23703673 |
KASUMI-1 | - | Growth Inhibition Assay | 72 h | IC50=170±51 nM | 25576074 |
KG-1 | - | Growth Inhibition Assay | 72 h | IC50=150±67 nM | 25576074 |
KMCH-1 | 200 nM | Apoptosis Assay | 24 h | induces apoptosis | 23703673 |
LNCaP | 10/50/250 nM | Growth Inhibition Assay | 24 h | IC50<10 nM | 23884428 |
MCF7/LTED | 2.5-40 nM | Growth Inhibition Assay | 5 d | inhibits cell growth in a dose-dependent manner | 25480943 |
MOLM-13 | - | Growth Inhibition Assay | 72 h | IC50=57±44 nM | 25576074 |
MV-4-11 | - | Growth Inhibition Assay | 72 h | IC50=16±6 nM | 25576074 |
Mz-ChA-1 | 200 nM | Apoptosis Assay | 24 h | induces apoptosis | 23703673 |
NCI-H460 | - | Growth Inhibition Assay | - | EC50 = 21 nM | 19383823 |
NOMO-1 | - | Growth Inhibition Assay | 72 h | IC50=145±7 nM | 25576074 |
OCI-AML3 | - | Growth Inhibition Assay | 72 h | IC50=90±51 nM | 25576074 |
PC3 | 10/50/250 nM | Growth Inhibition Assay | 24 h | IC50∼600 nM | 23884428 |
Raji | - | Growth Inhibition Assay | - | EC50 = 37 nM | 19383823 |
RT4 | - | Growth Inhibition Assay | 48 h | IC50=111.27 nM | 23792639 |
SF188 | 50-150 nM | Growth Inhibition Assay | 72 h | inhibits cell proliferation | 23887645 |
SKM-1 | - | Growth Inhibition Assay | 72 h | IC50=95±52 nM | 25576074 |
T24 | - | Growth Inhibition Assay | 48 h | IC50=204.91 nM | 23792639 |
T98G | 50-150 nM | Growth Inhibition Assay | 72 h | inhibits cell proliferation | 23887645 |
THP-1 | - | Growth Inhibition Assay | 72 h | IC50=56±39 nM | 25576074 |
THP-1 | - | Growth Inhibition Assay | - | EC50 = 36 nM | 19383823 |
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
---|
NCT01023958 | Neoplasms | Phase 2 | Completed | - | United States, California ... more >> 1230.2.5 Boehringer Ingelheim Investigational Site Beverly Hills, California, United States 1230.2.10 Boehringer Ingelheim Investigational Site Los Angeles, California, United States United States, Florida 1230.2.34 Boehringer Ingelheim Investigational Site Miami, Florida, United States 1230.2.29 Boehringer Ingelheim Investigational Site Orlando, Florida, United States United States, Illinois 1230.2.6 Boehringer Ingelheim Investigational Site Chicago, Illinois, United States 1230.2.17 Boehringer Ingelheim Investigational Site Joliet, Illinois, United States United States, Louisiana 1230.2.24 Boehringer Ingelheim Investigational Site Metairie, Louisiana, United States United States, Maryland 1230.2.1 Boehringer Ingelheim Investigational Site Baltimore, Maryland, United States United States, Nevada 1230.2.25 Boehringer Ingelheim Investigational Site Las Vegas, Nevada, United States 1230.2.36 Boehringer Ingelheim Investigational Site Las Vegas, Nevada, United States United States, New Hampshire 1230.2.19 Boehringer Ingelheim Investigational Site Lebanon, New Hampshire, United States United States, New York 1230.2.20 Boehringer Ingelheim Investigational Site New York, New York, United States 1230.2.23 Boehringer Ingelheim Investigational Site New York, New York, United States United States, North Carolina 1230.2.12 Boehringer Ingelheim Investigational Site Charlotte, North Carolina, United States United States, Pennsylvania 1230.2.4 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States United States, Texas 1230.2.38 Boehringer Ingelheim Investigational Site Beaumont, Texas, United States 1230.2.41 Boehringer Ingelheim Investigational Site Tyler, Texas, United States 1230.2.43 Boehringer Ingelheim Investigational Site Webster, Texas, United States United States, Virginia 1230.2.44 Boehringer Ingelheim Investigational Site Fairfax, Virginia, United States Taiwan 1230.2.51 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1230.2.50 Boehringer Ingelheim Investigational Site Taipei, Taiwan Collapse << |
NCT00969553 | Neoplasms | Phase 1 | Completed | - | Taiwan ... more >> 1230.16.886002 Boehringer Ingelheim Investigational Site Tainan, Taiwan 1230.16.886001 Boehringer Ingelheim Investigational Site Taipei, Taiwan Collapse << |
NCT01023958 | - | - | Completed | - | - |
NCT01121406 | Ovarian Neoplasms | Phase 2 | Completed | - | Belgium ... more >> 1230.18.32003 Boehringer Ingelheim Investigational Site Brussel, Belgium 1230.18.32004 Boehringer Ingelheim Investigational Site Edegem, Belgium 1230.18.32002 Boehringer Ingelheim Investigational Site Gent, Belgium 1230.18.32001 Boehringer Ingelheim Investigational Site Leuven, Belgium France 1230.18.3321A Boehringer Ingelheim Investigational Site Angers Cedex 9, France 1230.18.3307A Boehringer Ingelheim Investigational Site Bordeaux cedex, France 1230.18.3301A Boehringer Ingelheim Investigational Site Caen, France 1230.18.3322A Boehringer Ingelheim Investigational Site Lille Cedex, France 1230.18.3313A Boehringer Ingelheim Investigational Site Lyon, France 1230.18.3312A Boehringer Ingelheim Investigational Site Nantes cedex 02, France 1230.18.3308A Boehringer Ingelheim Investigational Site Nice cedex, France 1230.18.3314A Boehringer Ingelheim Investigational Site Paris Cedex 20, France 1230.18.3302A Boehringer Ingelheim Investigational Site Paris, France 1230.18.3309A Boehringer Ingelheim Investigational Site Pierre-Bénite cedex, France 1230.18.3305A Boehringer Ingelheim Investigational Site Reims cedex, France 1230.18.3320A Boehringer Ingelheim Investigational Site Saint-Brieuc cedex, France 1230.18.3311A Boehringer Ingelheim Investigational Site Strasbourg, France 1230.18.3310A Boehringer Ingelheim Investigational Site Toulouse Cedex 9, France 1230.18.3315A Boehringer Ingelheim Investigational Site Vandoeuvre les Nancy cedex, France Slovakia 1230.18.42101 Boehringer Ingelheim Investigational Site Bratislava, Slovakia 1230.18.42103 Boehringer Ingelheim Investigational Site Poprad, Slovakia Spain 1230.18.34006 Boehringer Ingelheim Investigational Site Badalona, Spain 1230.18.34001 Boehringer Ingelheim Investigational Site Barcelona, Spain 1230.18.34005 Boehringer Ingelheim Investigational Site Barcelona, Spain 1230.18.34007 Boehringer Ingelheim Investigational Site Girona, Spain 1230.18.34004 Boehringer Ingelheim Investigational Site L'Hospitalet de Llobregat, Spain 1230.18.34002 Boehringer Ingelheim Investigational Site Madrid, Spain 1230.18.34003 Boehringer Ingelheim Investigational Site Madrid, Spain Sweden 1230.18.46005 Boehringer Ingelheim Investigational Site Linköping, Sweden 1230.18.46001 Boehringer Ingelheim Investigational Site Stockholm, Sweden 1230.18.46003 Boehringer Ingelheim Investigational Site Uppsala, Sweden Collapse << |
NCT01121406 | - | - | Completed | - | - |
NCT00804856 | Leukemia, Myeloid, Acute | Phase 2 | Active, not recruiting | August 2, 2019 | Austria ... more >> LKH-Univ. Hospital Graz Graz, Austria, 8036 Belgium AZ Sint-Jan Brugge Brugge, Belgium, 8000 Brussels - UNIV Saint-Luc Bruxelles, Belgium, 1200 UZ Leuven Leuven, Belgium, 3000 Canada, Migration Data CHUS Fleurimont Sherbrooke, Migration Data, Canada, J1H 5N4 Canada, Ontario Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Canada, Quebec Montreal General Hospital - McGill University Health Centre Montreal, Quebec, Canada, H3G 1A4 France HOP Clémenceau, Hémato, Caen Caen, France, 14033 HOP, Centre Hospitalier René Dubos, Hémato, Paris Cergy Pontoise Cedex, France, 95303 HOP Dupuytren Limoges, France, 87042 HOP Herriot Lyon Cedex 03, France, 69437 CTR, fondation Paschetta, Hémato, Nice Nice Cedex 2, France, 06189 HOP Saint-Louis Paris cedex 10, France, 75475 CTR Henri Becquerel Rouen Cedex, France, 76088 Germany Campus Virchow-Klinikum, Berlin Berlin, Germany, 13353 Universitätsklinikum Frankfurt Frankfurt/Main, Germany, 60590 Universitätsklinikum Freiburg Freiburg, Germany, 79106 Universitätsklinikum Hamburg-Eppendorf Hamburg, Germany, 20246 Universitätsklinikum Heidelberg Heidelberg, Germany, 69120 Universitätsklinikum Schleswig-Holstein, Campus Kiel Kiel, Germany, 24116 Universitätsklinikum Münster Münster, Germany, 48149 Universitätsklinikum Ulm Ulm, Germany, 89081 Italy A.O. Spedali Civili di Brescia Brescia, Italy, 25123 ASST Grande Ospedale Metropolitano Niguarda Milano, Italy, 20162 Azienda Ospedaliera Policlinico di Modena Modena, Italy, 41100 Norway Haukeland Universitetssykehus Bergen, Norway, N-5021 Oslo Universitetssykehus HF, Ullevål sykehus Oslo, Norway, N-0450 Collapse << |
NCT00824408 | Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | - | Bahamas ... more >> 1230.5.00118 Boehringer Ingelheim Investigational Site Nassau, Bahamas Canada, Alberta 1230.5.00104 Boehringer Ingelheim Investigational Site Edmonton, Alberta, Canada Canada, British Columbia 1230.5.00114 Boehringer Ingelheim Investigational Site Kelowna, British Columbia, Canada 1230.5.00109 Boehringer Ingelheim Investigational Site Surrey, British Columbia, Canada 1230.5.00107 Boehringer Ingelheim Investigational Site Vancouver, British Columbia, Canada Canada, Ontario 1230.5.00105 Boehringer Ingelheim Investigational Site Hamilton, Ontario, Canada 1230.5.00119 Boehringer Ingelheim Investigational Site Kitchener, Ontario, Canada 1230.5.00116 Boehringer Ingelheim Investigational Site Oshawa, Ontario, Canada 1230.5.00108 Boehringer Ingelheim Investigational Site Ottawa, Ontario, Canada 1230.5.00110 Boehringer Ingelheim Investigational Site Toronto, Ontario, Canada Canada, Quebec 1230.5.00102 Boehringer Ingelheim Investigational Site Montreal, Quebec, Canada 1230.5.00106 Boehringer Ingelheim Investigational Site Montreal, Quebec, Canada Collapse << |
NCT02273388 | Neoplasms | Phase 1 | Active, not recruiting | August 26, 2022 | Belgium ... more >> 1230.1.32002 Boehringer Ingelheim Investigational Site Brussels, Belgium 1230.1.32001 Boehringer Ingelheim Investigational Site Leuven, Belgium Collapse << |
NCT01721876 | Leukemia, Myeloid, Acute | Phase 3 | Active, not recruiting | December 31, 2019 | - |
NCT00824408 | - | - | Completed | - | - |
NCT01957644 | Myelodysplastic Syndromes ... more >> Leukemia, Myelomonocytic, Chronic Collapse << | Phase 1 | Terminated | - | France ... more >> Boehringer Ingelheim Investigational Site Marseille, France Boehringer Ingelheim Investigational Site Paris, France Germany Boehringer Ingelheim Investigational Site Berlin, Germany Boehringer Ingelheim Investigational Site Dresden, Germany Boehringer Ingelheim Investigational Site Düsseldorf, Germany Boehringer Ingelheim Investigational Site Frankfurt/Main, Germany Boehringer Ingelheim Investigational Site Freiburg, Germany Boehringer Ingelheim Investigational Site Hamburg, Germany Boehringer Ingelheim Investigational Site Hannover, Germany Boehringer Ingelheim Investigational Site Kassel, Germany Boehringer Ingelheim Investigational Site Leipzig, Germany Boehringer Ingelheim Investigational Site Mannheim, Germany Boehringer Ingelheim Investigational Site München, Germany Boehringer Ingelheim Investigational Site Ulm, Germany Collapse << |
NCT01206816 | Neoplasms | Phase 1 | Completed | - | Belgium ... more >> 1230.20.32001 Boehringer Ingelheim Investigational Site Bruxelles, Belgium 1230.20.32003 Boehringer Ingelheim Investigational Site Edegem, Belgium 1230.20.32002 Boehringer Ingelheim Investigational Site Gent, Belgium Collapse << |
NCT00969761 | Neoplasms | Phase 1 | Completed | - | Belgium ... more >> 1230.6.3201 Boehringer Ingelheim Investigational Site Bruxelles, Belgium 1230.6.3202 Boehringer Ingelheim Investigational Site Leuven, Belgium Collapse << |
NCT02198482 | Acute Myeloid Leukemia (AML) ... more >> High-risk Myelodysplastic Syndrome (MDS) Collapse << | Phase 2 | Terminated(development program... more >> of study drug volasertib was stopped by Boehringer Ingelheim due to manufacturing problems) Collapse << | - | Germany ... more >> Hospital Aschaffenburg Aschaffenburg, Germany, 63739 Helios Hospital Bad Saarow Bad Saarow, Germany, 15526 Vivantes Hospital Am Urban Berlin, Germany, 10967 Vivantes Hospital Neukölln Berlin, Germany, 12351 Charite Berlin Campus Virchow Hospital Berlin, Germany, 13353 Knappschaftskrankenhaus Bochum-Langendeer Bochum, Germany, 44892 University Hospital Bonn Bonn, Germany, 53105 Community Hospital Braunschweig Braunschweig, Germany, 38114 Hospital Darmstadt Darmstadt, Germany, 64283 University Hospital Düsseldorf Düsseldorf, Germany, 40225 Hospital Essen, Protestant Hospital Essen-Werden Essen, Germany, 45239 Hospital Esslingen Esslingen, Germany, 73730 Malteser Hospital St. Franziskus Flensburg, Germany, 24939 Hospital Frankfurt-Höchst Frankfurt, Germany, 65929 Medical Care Unit Osthessen Fulda, Germany, 36043 University Hospital Gießen Gießen, Germany, 35392 Wilhelm-Anton-Hospital Goch Goch, Germany, 47574 University Hospital Göttingen Göttingen, Germany, 37075 University Hospital Hamburg-Eppendorf Hamburg, Germany, 20246 Asklepios Hospital Altona Hamburg, Germany, 22763 Hospital Hanau Hanau, Germany, 63450 KRH Hospital Siloah-Oststadt-Heidehaus Hannover, Germany, 30459 Hannover Medical School Hannover, Germany, 30625 SLK-Hospital Heilbronn Heilbronn, Germany, 74078 Marienhospital Herne Herne, Germany, 44625 University Hospital des Saarlandes Homburg/Saar, Germany, 66421 Community Hospital Karlsruhe Karlsruhe, Germany, 76133 University Hospital Schleswig-Holstein Kiel, Germany, 24105 Caritas Hospital Lebach Lebach, Germany, 66822 Hospital Lippe-Lemgo Lemgo, Germany, 32657 University Hospital Magdeburg Magdeburg, Germany, 39120 University Hospital Johannes Gutenberg Mainz Mainz, Germany, 55131 Johannes Wesling Hospital Minden Minden, Germany, 32429 Stauferklinikum Schwäbisch-Gmünd Mutlangen, Germany, 73557 Hospital Schwabing München, Germany, 80804 Hospital rechts der Isar München München, Germany, 81675 Hospital Oldenburg Oldenburg, Germany, 26133 Hospital Passau Passau, Germany, 94032 Hospital Stuttgart Stuttgart, Germany, 70174 Diakonie Hospital Stuttgart Stuttgart, Germany, 70176 Hospital Traunstein Traunstein, Germany, 83278 Mutterhaus der Borromäerinnen Trier, Germany, 54290 Hospital Barmherzige Brüder Trier Trier, Germany, 54292 University Hospital Tübingen Tübingen, Germany, 72076 University Hospital Ulm Ulm, Germany, 89081 Collapse << |
NCT01022853 | - | - | Completed | - | - |
NCT01145885 | Neoplasms | Phase 1 | Completed | - | Hungary ... more >> 1230.23.36001 Boehringer Ingelheim Investigational Site Budapest, Hungary Collapse << |
NCT01022853 | Neoplasms | Phase 1 | Completed | - | Italy ... more >> 1230.7.39002 Boehringer Ingelheim Investigational Site Ancona, Italy 1230.7.39001 Boehringer Ingelheim Investigational Site Milano, Italy Collapse << |
NCT01971476 | - | - | Completed | - | - |
NCT02875002 | Relapsed and Refractory Aggres... more >>sive B- and T-cell Lymphomas Lymphoma Collapse << | Phase 1 | Withdrawn | September 2018 | United States, Connecticut ... more >> Yale Cancer Center New Haven, Connecticut, United States, 06511 United States, Maryland Sidney Kimmel Comprehensive Cancer Baltimore, Maryland, United States, 21287 United States, Virginia Massey Cancer Center Richmond, Virginia, United States, 23298 Collapse << |
NCT01971476 | Leukemia Neop... more >>lasms Collapse << | Phase 1 | Completed | - | Belgium ... more >> UNIV UZ Gent Gent, Belgium, 9000 Czechia University Hospital Motol Prague, Czechia, 150 06 France INS Curie Paris, France, 75248 Germany Universitätsklinikum Köln (AöR) Köln, Germany, 50937 Italy Osp. Pediatrico Bambin Gesù Roma, Italy, 00165 Collapse << |
NCT01772563 | Neoplasms | Phase 1 | Active, not recruiting | April 15, 2019 | Hungary ... more >> PRA Hungary Ltd., Phase I. Clinical Pharmacology Unit Budapest, Hungary, 1077 National Institute of Oncology Budapest, Hungary, 1122 Collapse << |
NCT02757248 | PTCL CTCL | Phase 1 | Withdrawn(Boehringer Ingelheim... more >> is discontinuing their volasertib development program) Collapse << | - | - |
NCT02003573 | Leukemia, Myeloid, Acute | Phase 1 | Terminated | - | United States, Connecticut ... more >> Boehringer Ingelheim Investigational Site New Haven, Connecticut, United States United States, Missouri Boehringer Ingelheim Investigational Site St. Louis, Missouri, United States United States, New York Boehringer Ingelheim Investigational Site Lake Success, New York, United States United States, Texas Boehringer Ingelheim Investigational Site Houston, Texas, United States Collapse << |
NCT01348347 | Neoplasms | Phase 1 | Completed | - | Japan ... more >> 1230.15.001 National Cancer Center Hospital, Chuo-ku, Tokyo, Japan Collapse << |
NCT02905994 | AML | Phase 1 | Withdrawn(Funding Withdrawn) | - | United States, Massachusetts ... more >> Massachusetts general Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Collapse << |
NCT01348347 | - | - | Completed | - | - |
NCT02527174 | Leukemia, Myeloid, Acute ... more >> Leukemia, Monocytic, Acute Leukemia, Myelomonocytic, Acute Leukemia, Erythroblastic, Acute Leukemia, Megakaryoblastic, Acute Collapse << | Phase 1 | Withdrawn(Volasertib no longer... more >> available) Collapse << | September 2018 | Canada, Alberta ... more >> Tom Baker Cancer Centre Calgary, Alberta, Canada, T2N 4N2 University of Alberta Hospital Edmonton, Alberta, Canada, T6G 2G3 Collapse << |
NCT02721875 | Myelodysplastic Syndromes | Phase 1 | Terminated | - | Japan ... more >> University of Fukui Hospital Fukui, Yoshida-gun, Japan, 910-1193 Collapse << |
NCT02861040 | Recurrent Adult Acute Lymphobl... more >>astic Leukemia Refractory Adult Acute Lymphoblastic Leukemia Collapse << | Phase 1 | Withdrawn | - | United States, California ... more >> Stanford University Palo Alto, California, United States, 94304 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21231 Collapse << |
NCT02721875 | - | - | Terminated | - | - |
NCT02201329 | Myelodysplastic Syndromes ... more >> Leukemia, Myelomonocytic, Chronic Collapse << | Phase 1 | Completed | - | Japan ... more >> Boehringer Ingelheim Investigational Site Aichi, Nagoya, Japan Boehringer Ingelheim Investigational Site Gunma, Maebashi, Japan Boehringer Ingelheim Investigational Site Nagasaki, Nagasaki, Japan Boehringer Ingelheim Investigational Site Tokyo, Sinagawa-ku, Japan Collapse << |
NCT02201329 | - | - | Completed | - | - |
NCT02722135 | Leukemia, Myeloid, Acute | Phase 1 | Withdrawn | September 2018 | Belgium ... more >> Boehringer Ingelheim Investigational Site Gent, Belgium Collapse << |
NCT01662505 | Leukemia, Myeloid, Acute | Phase 1 | Completed | - | Japan ... more >> Boehringer Ingelheim Investigational Site Chuo-ku, Tokyo, Japan Boehringer Ingelheim Investigational Site Isehara, Kanagawa, Japan Boehringer Ingelheim Investigational Site Maebashi, Gunma,, Japan Boehringer Ingelheim Investigational Site Nagasaki, Nagasaki, Japan Boehringer Ingelheim Investigational Site Nagoya-shi, Aichi, Japan Boehringer Ingelheim Investigational Site Yoshida-gun, Fukui, Japan Collapse << |
NCT01662505 | - | - | Completed | - | - |
靶点 | Description | IC50 |
---|---|---|
PLK1 | IC50:0.87nM |
联系我们
官方电话:400-920-2911
二维码
微信公众号 CSN官网